Drugs / Nerve Growth Factor, Recombinant Human
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00000842 | ? → Feb 1999 | HIV infectious disease, sensory peripheral neuropathy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nerve Growth Factor, Recombinant Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000842 ↗ |
| Known as | rhNGF | “To assess the efficacy, safety, and tolerability of recombinant human nerve growth factor ( rhNGF ) in the treatment of HIV-associated sensory neuropathy.” NCT00000842 ↗ |
| Action | Restore | “may provide a specific restorative treatment for HIV-associated painful sensory neuropathy” NCT00000842 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human nerve growth factor” NCT00000842 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00000842 ↗ |